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HPV16 E5 expression induces switching from FGFR2b
to FGFR2c and epithelial-mesenchymal transition
Danilo Ranieri1*, Francesca Belleudi1*, Alessandra Magenta1 and Maria Rosaria Torrisi1,2
1 Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Medicina Clinica e Molecolare, Sapienza Universita di Roma, Italy
2 Azienda Ospedaliera S. Andrea, Rome, Italy
The E5 oncoprotein of the human papillomavirus type 16 (HPV16 E5) deregulates epithelial homeostasis through the modulation of
receptor tyrosine kinases and their signaling. Accordingly, the fibroblast growth factor receptor 2b (FGFR2b/KGFR), epithelial splicing
transcript variant of the FGFR2, is down-modulated by the viral protein expression, leading to impairment of keratinocyte differentiation.
Here, we report that, in cell models of transfected human keratinocytes as well as in cervical epithelial cells containing episomal HPV16,
the down-regulation of FGFR2b induced by 16E5 is associated with the aberrant expression of the mesenchymal FGFR2c isoform as a con-
sequence of splicing switch: in fact, quantitative RT-PCR analysis showed that this molecular event is transcriptionally regulated by the
epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) and is able to produce effects synergistic with those caused by TGFb
treatment. Immunofluorescence analysis revealed that this altered FGFR2 splicing leads to changes in the specificity for the ligands FGFs
and in the cellular response, triggering epithelial-mesenchymal transition (EMT). Through 16E5 or FGFR2 silencing as well as inhibition of
FGFR2 activity we demonstrated the direct role of the viral protein in the receptor isoform switching and EMT, suggesting that these early
molecular events during HPV infection might represent additional mechanisms driving cervical transformation and tumor progression.
The fibroblast growth factor receptors (FGFRs) are receptor
tyrosine kinases (RTKs) expressed on different tissues and
involved in the control of cellular key processes such as
growth, differentiation, migration and survival.1,2 The recep-
tor extracellular domain is characterized by three immuno-
globulin (Ig) loops (IgI-III) and the Ig like-domains II and
III form the high affinity binding site for their ligands. Tissue
specific alternative splicing of the IgIII domain in FGFR1–3
generates IIIb and IIIc isoforms and is responsible for ligand
selection. While the FGFRIIIb isoforms are mostly expressed
in epithelial tissues, the FGFRIIIc isoforms are generally pres-
ent on mesenchymal cells: since also the ligand expression
patterns are characterized by tissue specificity, the FGF sig-
naling is tightly controlled in a paracrine and context-
dependent manner and is crucial for the epithelial-stromal
interaction and homeostasis.
FGF/FGFR signaling may play oncogenic roles in tumori-
genesis; however, through the triggering of cell differentiation,
receptor activation might lead to opposite tumor suppressive
outcome.3,4 In fact, deregulated and out-of-context oncogenic
FGFR signaling is frequently associated with carcinogenesis and
altered paracrine or autocrine loops of receptor activation are
often established in tumor progression. Interestingly, the
switching from the FGFRIIIb to the FGFRIIIc isoforms is
involved in epithelial-mesenchymal transition (EMT) and can-
cer progression.5,6 However, reduced FGFR expression and
loss-of function mutations are also frequently involved in the
tumorigenic process. These opposite roles have been reported
mostly in the case of FGFR2, whose alternative splicing gener-
ates the epithelial FGFR2IIIb isoform (FGFR2b, also named
keratinocyte growth factor receptor KGFR), which appears to
play an unusual and unique role acting as a tumor suppressor in
vitro and in vivo7,8 and the mesenchymal FGFR2IIIc (FGFR2c),
which exerts oncogenic activity in different types of cancer.1,3,4
The infection with high-risk genotypes of human papillo-
mavirus (HPV), such as the HPV16 and HPV18 viruses, is
known to be a major risk factor for cervical cancer and
appears to be responsible for its progression.9 Among the dif-
ferent viral products, the E5 oncoprotein of the HPV16 is
involved in cervical carcinogenesis through cooperation with
the other two viral oncogenes E6 and E7 and transforms epi-
thelial cells by deregulating cell growth, survival and differen-
tiation through the modulation of RTKs and of their
signalling.10,11 Consistent with this latter assumption, we
have recently proposed the existence of a functional crosstalk
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among the HPV16 E5 protein and the FGFR2b/KGFR: in
fact, we have shown that 16E5 expression induces alteration
of the signaling and endocytic traffic as well as down-
modulation of the receptor12,13 and this molecular interplay
might be crucial in perturbing the cell proliferation/differen-
tiation and in driving tumorigenesis. Therefore, with the aim
to further clarify the molecular events underlying this trans-
forming interplay, we analyzed here if the FGFR2b/KGFR
down-modulation induced by HPV16 E5 expression,
observed in our previous studies, would be only one of the
consequences of a more complex mechanism of FGF/
FGFR2 signaling deregulation involving switching from
FGFR2b to FGFR2c isoforms, changes in the specificity for
the ligands FGFs and in the cellular response as well as trig-
gering of EMT.
Material and Methods
Cells and treatments
The human keratinocyte cell line HaCaT14 was cultured in
Dulbecco’s DMEM, supplemented with 10% fetal bovine
serum plus antibiotics. HaCaT cells stably transfected with the
construct pMSG 16E5 (HaCaT pMSG E5) or with the empty
vector (HaCaT pMSG)15 were cultured as reported above and
were treated with 1 lM dexamethasone (Dex) for different
times (6, 12 and 24 hr) to induce 16E5 expression. The human
cervical keratinocyte cell line W12 initiated from a low-grade
cervical lesion,16 which retains 100 to 200 copies of the
HPV16 episomes per cell,16–18 was cultured as previously
described16 and used at the passage 6 (W12p6). Primary cul-
tures of human keratinocytes and human fibroblasts derived
from healthy skin (HKs and HFs, respectively) were obtained
from patients attending the Dermatology Unit of the Sant’An-
drea Hospital of Rome; all patients were extensively informed
and their consent for the investigation was given and collected
in written form in accordance with guidelines approved by the
management of the Sant’Andrea Hospital. Primary cells were
isolated and cultured as previously described.19,20
HaCaT cells were transiently transfected with pCI-neo
expression vector containing 16E5-HA21 (HaCaT E5) or with
the pCI-neo empty vector (HaCaT pCI-neo). Alternatively,
HaCaT cells were cotransfected with the above pCI-neo vec-
tors and with pMXs-IRES-blast2 Esrp1-FF retroviral expres-
sion construct (kindly provided by Dr. Russ Carstens,
University of Pennsylvania School of Medicine, Philadelphia,
PA; HaCaT ESRP1) or with empty vectors (HaCaT EVs).
W12p6 cells were transfected with pMXs-IRES-blast2 Esrp1-
FF (W12p6 ESRP1) or with empty vector (W12p6 EV). For
transfections, jetPEITM DNA Transfection Reagent (Polyplus-
transfection, New York, NY) or Fugene HD (Promega, Madi-
son, WI) were used according to manufacturer’s instructions.
For RNA interference and FGFR2 or 16E5 silencing,
HaCaT cells were transfected with Bek small interfering RNA
(FGFR2 siRNA) (Santa Cruz Biotechnology, Santa Cruz, CA)
or with an unrelated siRNA as a control (control siRNA),
while W12p6 cells were transfected with the E5 siRNA
sequence (50-TGGTATTACTATTGTGGATAA-30)22 or the
control sequence (50-AATTCTCCGAACGTGTCACGT-30)
(Qiagen, Valencia, CA), using Lipofectamine 2000 Transfec-
tion Reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol.
For growth factors stimulation, cells were serum starved
or incubated with 20 ng/ml KGF (Upstate Biotechnology,
Lake Placid, NY) or with 20 ng/ml FGF2 (PeproTech, Lon-
don, UK) for 24 hr at 37C or with 10 ng/ml TGF-b1
(PeproTech) for 48 hr at 37C.
For inhibition of FGFR2b and FGFR2c-specific tyrosine
kinase activity, cells were preincubated with the specific
FGFR2 tyrosine kinase inhibitor SU5402 25 lM (Calbiochem,
Nottingham, UK) for 1 hr before treatments with growth
factors.
Microinjection
Microinjection was performed with an Eppendorf microinjec-
tor (Eppendorf, Hamburg, Germany) and an inverted micro-
scope (Zeiss, Oberkochen, Germany). A mixture of 100 nM
Bek siRNA (Santa Cruz) 100 ng/ml pCI-neo 16E5-HA and
1 mg/ml rabbit IgG (Cappel Research Products, Durham,
NC) in PBS were microinjected in the cytoplasm of HaCaT
cells to simultaneously induce RNA interference and conse-
quent FGFR2b/FGFR2c silencing and 16E5 overexpression.
Unrelated siRNA was microinjected as negative control.
Immunofluorescence
HaCaT keratinocytes and W12p6 cells, grown on coverslips,
were fixed with 4% paraformaldehyde in PBS for 30 min at
25C followed by treatment with 0.1 M glycine for 20 min at
25C and with 0.1% Triton X-100 for additional 5 min
at 25C to allow permeabilization. Cells were then incubated
What’s new?
Of the fibroblast growth factor receptor (FGFR) pathways implicated in cancer, those involving the epithelial isoform FGFR2b,
which is potentially tumor suppressive, and the mesenchymal isoform FGFR2c, which is potentially oncogenic, are of special
interest. This study shows that a splicing switch from FGFR2b to FGFR2c occurs in the presence of the E5 oncoprotein of
human papillomavirus (HPV) type 16, which downregulates FGFR2b. The switch leads to alterations in ligand specificity and
cellular response, which appear to be associated with epithelial-mesenchymal transition. The findings suggest that this
switching drives HPV-associated cervical transformation and tumor progression.
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for 1 hr at 25C with the following primary mouse monoclo-
nal antibodies: anti-HA (1:50 in PBS; Covance, Berkeley, CA),
anti-E cadherin (1:50 in PBS; Dako, Carpinteria, CA), anti-
vimentin (1:50 in PBS; Dako) or anti-b4 integrin (1:50 in PBS;
Santa Cruz). The primary antibodies were visualized using
goat anti-mouse IgG-FITC (1:50 in PBS; Cappel) for 30 min
at 25C. Goat anti-rabbit IgG-Texas Red (1:100 in PBS; Jack-
son Immunoresearch Laboratories, West Grove, PA) was used
to identify microinjected cells. Actin cytoskeleton was visual-
ized using TRITC-phalloidin (1:100 in PBS; Sigma-Aldrich,
Saint Louis, MO). Nuclei were stained with DAPI (1:1000 in
PBS; Sigma). Coverslips were finally mounted with mowiol
(Sigma) for observation. Fluorescence signals were analyzed by
scanning cells in a series of sequential sections with an Apo-
Tome System (Zeiss); image analysis was performed by the
Axiovision software (Zeiss) and 3D reconstruction of a selec-
tion of three central optical sections was shown in each figure.
Quantitative analysis of the percentage of cells expressing the
different epithelial or mesenchymal markers was assessed
counting for each sample a total of 100 cells, randomly
observed in 10 microscopic fields from three different experi-
ments. To discriminate between positive and negative cells, the
fluorescence signal intensity was analyzed using the KS300 3.0
Image Processing System (Zeiss) and the cut-off value was
selected for both unstimulated or growth factor-stimulated
samples. Results have been expressed as mean values6 stan-
dard deviation (SD). p values were calculated using Student’s t
test and significance level has been defined as p< 0.05.
Western blot analysis
HaCaT cells were lysed in a buffer containing 50 mM HEPES,
pH 7.5, 150 mM NaCl, 1% glycerol, 1% Triton X-100, 1.5 mM
MgCl2, 5 mM EGTA, supplemented with protease inhibitors
(10 mg/ml aprotinin, 1 mM PMSF and 10 mg/ml leupeptin)
and phosphatase inhibitors (1 mM sodium orthovanadate,
20 mM sodium pyrophosphate and 0.5 M NaF); 50 mg of total
protein were resolved under reducing conditions by 12% SDS-
PAGE and transferred to reinforced nitrocellulose (BA-S 83,
Schleider and Schuell, Keene, NH). The membranes were
blocked with 5% non fat dry milk in PBS 0.1% Tween 20 and
incubated with anti-HA monoclonal antibody (Covance) or
anti-Bek (C-17, Santa Cruz) polyclonal antibodies followed by
enhanced chemiluminescence detection (ECL, Amersham,
Alington Heights, IL). The membranes were rehydrated and
probed again with anti-actin (Sigma) monoclonal antibody, to
estimate the protein equal loading.
Primers
Oligonucleotide primers for target genes and for the house-
keeping gene were chosen with the assistance of the Oligo
5.0 computer program (National Biosciences, Plymouth, MN)
and purchased from Invitrogen. The following primers were
used: for FGFR2b/KGFR target gene: 50-CGTGGAAAA
GAACGGCAGTAAATA-3 (sense), 50-GAACTATTTATCCC
CGAGTGCTTG-30 (anti-sense); for FGFR2c target gene: 50-
TGAGGACGCTGGGGAATATACG-3 (sense), 50- TAGTCT
GGGGAAGCTGTAATCTCCT 230 (anti-sense); for HPV
16E5 gene 50-CGCTGCTTTTGTCTGTGTCT-30 (sense), 50-
GCGTGCATGTGTATGTATTAAAAA-30 (antisense); for
ESRP1 target gene 50- GGCTCGGATGAGAAGGAGTT-30
(sense), 50-GCACTTCGTGCAACTGTCC-30 (antisense); for
ESRP2 target gene 50-GCTGTTATCCTCCATCTACTCAA
AG-30 (sense), 50- GTCCACCACATCAGCCTTG-30 (anti-
sense); for the 18S rRNA housekeeping gene: 50-AACCAAC
CCGGTCAGCCCCT-30 (sense), 50-TTCGAATGGGTCGTCG
CCGC-30 (antisense). For each primer pair, we performed
no-template control and no-reverse-transcriptase control (RT
negative) assays, which produced negligible signals.
RNA extraction and cDNA synthesis
RNA was extracted using the TRIzol method (Invitrogen)
according to manufacturer’s instructions and eluted with 0,1%
diethylpyrocarbonate-treated water. Each sample was treated
with DNAase I (Invitrogen). Total RNA concentration was
quantitated by spectrophotometry; 1 mg of total RNA was used
to reverse transcription using iScriptTM cDNA synthesis kit
(Bio-Rad) according to manufacturer’s instructions.
PCR amplification and real-time quantitation
Real-time PCR was performed using the iCycler Real-Time
Detection System (iQ5 Bio-Rad) with optimized PCR condi-
tions. The reaction was carried out in 96-well plate using iQ
SYBR Green Supermix (Bio-Rad) adding forward and reverse
primers for each gene and 1ml of diluted template cDNA to a
final reaction volume of 15 ml. All assays included a negative
control and were replicated three times. The thermal cycling
program was performed as described.12 Real-time quantita-
tion was performed with the help of the iCycler IQ optical
system software version 3.0a (Bio-Rad Laboratories), accord-
ing to the manufacturer’s manual. Results are reported as
mean6 standard error (SE) from three different experiments
in triplicate. Student’s t test was performed and significance
levels have been defined as p< 0.05.
Results
HPV16 E5 down-modulates FGFR2b and induces FGFR2c
expression in human keratinocytes
Since deregulated and out-of-context signaling of the FGFRs
appear to play a role in carcinogenesis and because we have
recently demonstrated that FGFR2b/KGFR is down-
modulated at both transcript and protein levels by the
expression of the oncogenic HPV16 E5 product,12,13 we
investigated here if the decreased expression of the FGFR2b
epithelial splicing isoform induced by the viral protein would
correspond to an aberrant expression of the FGFR2c mesen-
chymal splicing variant. To this aim, we used the human
keratinocyte HaCaT cell line, spontaneously immortalized
from a primary culture of keratinocytes14 and previously
used as a powerful cellular model in numerous studies
including ours,12,13 on the effects of HPV16 E5.
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First, the specificity of the primers, designed to discrimi-
nate among the epithelial FGFR2b and mesenchymal FGFR2c
isoforms, was tested not only on the HaCaT cells, but also
on skin-derived primary cultured keratinocytes (HKs) and
fibroblasts (HFs). The mRNA transcript levels of FGFR2b
and FGFR2c were quantitated by real-time relative RT–PCR
using 18S rRNA as housekeeping gene: in accordance with
the tissue specificity of the two splice variants, the FGFR2b
appeared expressed exclusively on HKs and HaCaT keratino-
cytes (Fig. 1a, left panels), while the FGFR2c isoform was
present only on the HFs (Fig. 1a, right panels). Then, to eval-
uate the effects of 16E5 on the expression of the two receptor
Figure 1.
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splicing products, pre-confluent HaCaT cells were transiently
transfected with pCI-neo E5-HA expression vector21 (HaCaT
E5) or with the empty vector alone (HaCaT pCI-neo) as pre-
viously described.12,13 The mRNA transcript levels of 16E5,
FGFR2b and FGFR2c were quantitated as above and the
16E5 mRNA expression levels were normalized with respect
to the levels of the viral protein transcript in the HPV16-
positive cervical epithelial cell line W1216 at the passage 6
(W12p6) as previously reported.13,23 The results showed that,
as expected,12,13 the expression of 16E5 in the HaCaT trans-
fected cells led to a clear decrease of FGFR2b expression (Fig.
1b, central panel). In contrast, new and high expression the
FGFR2c was found in the HaCaT E5 cells (Fig. 1b, right
panel), suggesting that the viral protein is able to interfere
with the correct transcription and splicing of the FGFR2
gene which occurs in the physiological epithelial context.
To confirm the effects of 16E5 on FGFR2b/2c differential
expression also in a cell model of stable transfection, in which
the expression of the viral protein would be under the control
of an inducible promoter, we performed the real-time RT-PCR
analysis as above using HaCaT cells stably transfected with the
construct pMSG 16E5 (HaCaT pMSG E5),15 in which the
expression of the viral protein was progressively induced, by
treatment with Dex 1 mM, in a time-dependent manner (6, 12
and 24 hr of treatment, Fig. 1c, left panel). HaCaT pMSG cells
were used as negative control. The results showed that, while
the transcript levels of FGFR2b progressively decreased (Fig.
1c, central panel) upon treatment with Dex at 12 and 24 hr,
concomitant with the increasing amounts of 16E5 mRNA (Fig.
1c, left panel), the FGFR2c levels appeared clearly increased at
12 hr of Dex treatment and reaching the maximum of induc-
tion at that time point (Fig. 1c, right panel), suggesting that
16E5 might be directly responsible for an altered splicing.
16E5 triggers FGFR2b to FGFR2c isoform switch through
down-modulation of ESRPs
It is known that the epithelial splicing regulatory proteins 1
and 2 (ESRP1 and ESRP2) control alternative splicing events
of a number of genes,24 including the FGFR2.5 Therefore, to
demonstrate that the changes in FGFR2b and FGFR2c
expression, occurring in the presence of 16E5, are the conse-
quence of a ESRP-dependent switch of the mutually exclusive
splice variants, we evaluated by real-time RT-PCR as above
the transcript levels of ESRP1 and ESRP2 in the HaCaT cells
transfected with E5 transiently (HaCaT E5, Fig. 2a) or in a
stable inducible manner (HaCaT pMSG E5, Fig. 2b). In both
experimental models, the mRNA levels of either ESRP1 or
ESRP2 appeared drastically decreased in cells expressing E5
compared with control cells transfected with the empty vec-
tors pCI-neo or pMSG (Figs. 2a and 2b), indicating that the
down-modulation of the ESRPs might represent the major
molecular mechanism involved in the isoform switch. Inter-
estingly, consistent with the peak of FGFR2c induction in
HaCaT pMSG E5 cells after 12 hr of treatment with Dex
(Fig. 1c), both ESRP1 and 2 reached their maximal mRNA
expression after 12 hr Dex (Fig. 2b), providing a further sug-
gestion of the ESRP involvement in the process.
To confirm that the receptor switch triggered by E5 is
directly regulated by ESRPs, we overexpressed ESRP1 in the
HaCaT E5 cells by transient cotransfection (HaCaT E5/
ESRP1) as described in Material and Methods. Control cells
(HaCaT EVs) were cotransfected with the two empy vectors
(pCI-neo and pMXs-IRES-blast2). In accordance with the
suggested major role of ESRPs in regulating the splicing
event induced by 16E5, the restored expression of ESRP1
(Fig. 2c, left panel) was able to contrast the effect of the viral
protein, leading to a significant increase in the mRNA
expression of the FGFR2b variant (Fig. 2c, central panel) and
a decrease in that of FGFR2c compared with HaCaT E5 cells
(Fig. 2c, right panel).
Because the tissue-specific isoform splicing of FGFRs is
triggered by TGFb for driving EMT,6,25 we wondered if the
expression of E5 would amplify the effects of TGFb1 treat-
ment on the FGFR2 switch and ESRP down-modulation. To
this aim, HaCaT E5 and HaCaT pCI-neo cells were treated
with TGFb1 for 48h and then analyzed by real time RT-PCR
as above: incubation with the growth factor of the control
cells, transfected with the empty vector pCI-neo, caused a
decreasing of FGFR2b and increasing of the FGFR2c expres-
sion (Fig. 2d), as a result of the splicing switch consequent to
the expected down-modulation of ESRP1 and ESRP2 induced
by the treatment (Fig. 2e). Consistent with our hypothesis,
Figure 1. HPV16 E5 changes the expression of FGFR2b and FGFR2c mRNA transcripts. (a) FGFR2b and FGFR2c transcript levels were quanti-
tated by real-time relative RT-PCR in HaCaT cells and in primary human epidermal keratinocytes (HKs) or dermal fibroblasts (HFs), confirming
the tissue specific expression of FGFR2b on the epithelial cells and that of FGFR2c on the fibroblasts. (b) The 16E5 mRNA (left panel),
FGFR2b mRNA (central panel) and FGFR2c mRNA (right panel) were quantitated in HaCaT cells transfected with pCI-neo E5-HA expression
vector (HaCaT E5) compared with the empty vector alone (HaCaT pCI-neo). The 16E5 mRNA expression levels were normalized with respect
to the levels of the viral protein mRNA in the subclone W12p6 of the HPV16-positive cervical epithelial cell line W12 (left panel). In HaCaT
E5 cells, the decreased expression of the FGFR2b epithelial isoform corresponds to the appearance of the FGFR2c mesenchymal variant. (c)
HaCaT pMSG E5 cells and HaCaT pMSG used as negative control were treated with Dex for different times (6, 12 and 24 hr). The 16E5 (left
panel), FGFR2b (central panel) and FGFR2c (right panel) transcript levels were estimated by real-time RT-PCR: in HaCaT pMSG E5 cells, the
increasing expression of the viral protein upon Dex treatment leads to a decrease of FGFR2b and appearance of FGFR2c clearly detectable
at the 12 h time point. Results are expressed as mean values 6 SE. Student’s t test was performed as reported in Material and Methods
and significance level has been defined as follows: (b) * p<0.05 vs HaCaT pCI-neo cells; (c) * NS vs the corresponding Dex-untreated cells,
**, ^ p<0.05 vs the corresponding corresponding HaCaT pMSG cells treated with Dex for 6 hr, ***, ^ p<0.05 vs the corresponding cells
treated with Dex for 6 hr, ****,^^, ^^ NS vs the corresponding cells treated with Dex for 12 hr.
C
an
ce
r
C
el
l
B
io
lo
gy
Ranieri et al. 65
Int. J. Cancer: 137, 61–72 (2015) VC 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.
these molecular events triggered by TGFb1 were magnified
in cells expressing 16E5 (Figs. 2d and 2e), suggesting a syner-
gistic effect produced by the viral protein in conjunction with
the growth factor stimulation. 16E5 promotes EMT through
FGFR2b to FGFR2c switch and it changes the cell response
to FGFR2 ligands.
Figure 2.
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Since it has been shown that switching from the
FGFRIIIb to the FGFRIIIc isoforms is involved in EMT and
cancer progression5,6 and that this appears to be a conse-
quence of a change in sensitivity of the transitioning cells to
the FGFs, from the epithelial specific KGF/FGF7 to the mes-
enchymal specific FGF2,6 we wondered whether also the E5
viral protein, similarly to TGFb, might be able to promote
EMT through this molecular event. Therefore, we first ana-
lyzed if the presence of E5 in the HaCaT keratinocytes
would be associated with morphological features and actin
cytoskeletal reorganization reminiscent of an ongoing EMT
process: in agreement with our hypothesis, a clear shift
from the polygonal epithelial versus the spindle mesenchy-
mal morphology was observed in a portion of the HaCaT
E5 cells, positively stained with anti-HA monoclonal anti-
body to visualize the viral protein (Fig. 3a). Double immu-
nofluorescence labeling with TRITC-conjugated phalloidin,
which binds to filamentous actin, revealed the appearance
of stress fibers, common characteristic of fibroblast-like
cells, in the more elongated E5-positive HaCaT keratino-
cytes (Fig. 3a, inset in the central panel), suggesting that
HPV16E5, similarly to the 16E6 and 16E7 viral prod-
ucts,26,27 may cause the EMT process.
To demonstrate the possible direct role played by FGFR2
in the EMT promotion induced by 16E5, we analyzed the
effects of the receptor depletion. To this aim, HaCaT cells
were transfected with small interfering RNA for FGFR2/Bek
(FGFR2 siRNA) or with an unrelated siRNA used as control
and western blot analysis using anti-Bek polyclonal antibod-
ies, which recognize both receptor splicing variants, con-
firmed the efficient depletion of the FGFR2 protein in FGFR2
siRNA-transfected cells (Fig. 3b). The equal loading was
assessed with anti-actin antibody. Then, we performed coin-
jection of E5 cDNA, to express the viral protein, with FGFR2
siRNA, to obtain receptor silencing and mouse IgG to iden-
tify the microinjected cells. In parallel, microinjection with
E5 cDNA and the unrelated siRNA was performed. Immuno-
fluorescence analysis to evaluate the EMT process, assessed
by the decrease of the plasma membrane epithelial marker E-
cadherin and the appearance of the cytoplasmic mesenchy-
mal marker vimentin, showed that unstimulated cells
expressing the E5 (Fig. 3c, E5 cDNA/control siRNA, -GFs)
maintained the epithelial phenotype observed also in control
cells transfected with the empty pCI-neo vector (Fig. 3c, left
panel) or in the uninjected cells surrounding the injected
ones, which indicates that, in the absence of growth factor
stimulation, the expression of 16E5 alone is not able to
induce EMT. Therefore, to ascertain whether the shift in sen-
sitivity to the growth factors specific for the two FGFR2 iso-
forms would play the major role in the process, we treated
the coinjected cells with the FGFR2b ligand KGF/FGF7 or
with the FGFR2c ligand FGF2: while the stimulation with
KGF did not cause relevant changes in cell morphology as
well as in EMT markers (Fig. 3c, central panels), treatment
with FGF2 induced the elongated mesenchymal morphology
associated with a clear decrease in E-cadherin and appear-
ance of vimentin signal (Fig. 3c, central panels). Consistent
with the above hypothesis that the FGFR2b/2c switch is cru-
cial in the E5-promoted EMT process, depletion of the
FGFR2 (Fig. 3c, right panel, E5 cDNA/FGFR2 siRNA) abol-
ished the effects observed upon FGF2 treatment, demonstrat-
ing that the transition is a direct consequence of the
switching from FGFR2b to FGFR2c.
The viral protein effects are exerted also in the context of
cervical epithelial cells containing episomal HPV16
To better establish the contribution of E5-induced FGFR2
altered splicing in the context of cervical carcinogenesis and
to further clarify the complex epithelial FGF-network of auto-
crine and paracrine interactions occurring in vivo and the
role of the stromal microenvironment in this network, we
used the well established in vitro model of cervical W12
cells,16 containing episomal HPV16, grown at early passage
(W12p6) as above (Fig. 1b). To this aim, W12p6 cells were
Figure 2. 16E5 induces FGFR2b/FGFR2c switching through down-regulation of ESRPs. (a) ESRP1 and ESRP2 transcript levels were quantitated by
real-time relative RT-PCR in HaCaT pCI-neo and HaCaT E5 cells: a clear decrease of both ESRP1 and ESRP2 mRNA is evident in cells expressing
the viral protein. (b) ESRP1 and ESRP2 transcription is down-regulated also in HaCaT pMSG E5 cells after the induction of the 16E5 expression
following Dex treatment: the peak of the ESRP down-modulation is reached after 12 h of treatment, concomitant with the maximal induction of
FGFR2c shown in Figure 1c. (c) Overexpression of ESRP1 in HaCaT E5 cells by transient cotrasfection (HaCaT E5/ESRP1), able to restore the
ESRP1 expression, leads to a significant enhancement of FGFR2b transcription and decrease of that of FGFR2c also in the presence of 16E5,
compared with HaCaT E5 cells transfected to the viral protein alone (HaCaT E5). ESRP1 and FGFR2b mRNA values were normalized respect to
the levels in HaCaT cells transfected with the two empty vectors (HaCaT EVs), while those of FGFR2c were normalized respect to HFs. (d,e)
HaCaT E5 and HaCaT pCI-neo were treated with TGFb1 10 ng/ml for 48 hr at 37C to trigger FGFR switching and the mRNA levels of FGFR2b
and FGFR2c (d) or of ESRP1 and ESRP2 (e) were quantitated by real time RT-PCR as above. TGFb1 treatment induces FGFR2b/FGFR2c isoform
switch (d) and down-modulation of ESRPs transcription (e). The presence of the viral protein in HaCaT E5 cells treated with the growth factor
produces a synergistic effect (d,e). Results are expressed as mean values 6 SE. Student’s t test was performed as reported in Material and
Methods and significance level has been defined as follows: (a) *, ** p<0.001 vs HaCaT pCI-neo cells; (b) *, ^ NS vs the corresponding Dex-
untreated cells, ** p<0.01 05 vs the corresponding Dex-untreated HaCaT pMSG cells, *** p<0.01 vs the corresponding Dex untreated cells,
****, ^^^^, ^^^ NS vs the corresponding cells treated with Dex for 12 hr, ^^ p<0.05NS vs the corresponding Dex-untreatedHaCaT pMSG
cells, ^^^ p<0.05 vs the corresponding Dex untreated cells; (c) *, *** p<0.05 vs HaCaT EVs cells, **, ****. ***** p<0.05 vs HaCaT E5 cells;
(d) * p<0.05 vs the corresponding TGFb1-untreated cells, ** p<0.01 vs the corresponding HaCaT pCI-neo cells, *** p<0.05 vs the corre-
sponding HaCaT pCI-neo cells; (e) ^ p<0.001 vs the corresponding TGFb1-untreated cells, ^^ p<0.05 vs the corresponding HaCaT pCI-neo
cells, ^^^ p<0.01 vs the corresponding TGFb1-untreated cells,^^^^ p<0.01 vs the corresponding HaCaT pCI-neo cells.
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Figure 3. 16E5 promotes EMT through FGFR2 isoform switch and modifies the response to FGFs. (a) HaCaT pCI-neo and HaCaT E5 cells,
grown in serum, were fixed and double immunofluorescence was performed using anti-HA monoclonal antibody, to visualize the 16E5
protein and TRITC-conjugated phalloidin, to analyze the actin cytoskeleton organization. Cell nuclei were visualized by DAPI. A portion
of HaCaT E5 cells, positively stained for the viral protein (green), shows spindle mesenchymal morphology (HaCaT E5, left panel) and
actin reorganization (red) with appearance of stress fibers (inset), while others (HaCaT E5, right panel) seem to maintain the polygonal
epithelial shape. Bar: 10 mm. (b) HaCaT cells were transfected with small interfering RNA for FGFR2/Bek (FGFR2 siRNA) to obtain recep-
tor silencing or with an unrelated siRNA used as control. Western blot analysis using anti-Bek polyclonal antibodies, recognizing both
FGFR2b/2c proteins, confirms that the receptor expression, shown by the specific 140 kDa band corresponding to the molecular weight
of FGFR2, is efficiently down-modulated in FGFR2 siRNA-transfected cells. The equal loading was assessed with anti-actin antibody. (c)
HaCaT cells were coinjected with FGFR2 siRNA, E5 cDNA and mouse IgG to identify the injected cells. Coinjection of E5 cDNA and an
unrelated siRNA was performed as control. After injection, cells were serum starved and then treated with the FGFR2b ligand KGF/FGF7
or with the FGFR2c ligand FGF2 before fixation. Alternatively, cells were kept in serum-free medium (-GFs) and then fixed. Immunofluo-
rescence analysis to evaluate the EMT process was performed with anti-Ecadherin or anti-vimentin monoclonal antibodies and injected
cells were visualized with anti-IgG polyclonal antibodies. Cell nuclei were visualized by DAPI. The pattern of staining observed in
injected cells was analyzed in comparison with untreated control pCI-neo transfected cells (left panels) and with the uninjected cells
surrounding the injected ones. In injected cells expressing E5 (asterisks in E5 cDNA/control siRNA), either unstimulated (-GFs) or
treated with KGF, the signal corresponding to the plasma membrane epithelial marker E-cadherin appears unmodified respect to con-
trol pCI-neo transfected or uninjected cells and no staining for the cytoplasmic mesenchymal marker vimentin is visible. In contrast,
treatment with FGF2 induces a clear decrease in E-cadherin staining and appearance of vimentin signal associated with an elongated
mesenchymal morphology. Depletion of the FGFR2 (E5 cDNA/FGFR2 siRNA, right panels) is able to abolish the effects observed upon
FGF2 treatment, since the injected cells mantain both the epithelial shape and the E-cadherin signal and are negative for the vimentin
EMT marker. Bar: 10 mm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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treated with TGFb1, as positive control of EMT induction, or
with KGF/FGF7 or FGF2 ligands to activate FGFR2b and
FGFR2c, respectively. Quantitative immunofluorescence anal-
ysis, performed to evaluate the percentages of positivity for
the EMT markers as described in Material and Methods,
revealed that the decrease of epithelial markers (E-cadherin
and b4-integrin), as well as the appearance of the mesenchy-
mal marker vimentin, in response to FGF2 was comparable
to that obtained upon TGFb1 stimulation (Fig. 4), confirm-
ing the EMT promotion in the pathological context of cervi-
cal cells expressing HPV16 E5. This effect was abolished in
the presence of the specific FGFR tyrosine kinase inhibitor
SU5402 (Fig. 4, right panel), indicating that receptor activa-
tion and signaling are required for the promotion of EMT.
To confirm also in this cellular model of cervical carcino-
genesis that the molecular mechanism of FGFR2 splicing is
Figure 4. FGF2 triggers EMT in cervical epithelial cells expressing HPV16 E5. W12p6 cells, containing episomal HPV16 and expressing 16E5 as
shown in Figure 1b, were treated with TGFb1, as positive control of EMT induction, or with KGF/FGF7 or FGF2 ligands to activate FGFR2b and
FGFR2c, respectively. Quantitative immunofluorescence analysis, using antibodies directed against the epithelial markers E-cadherin and b4-
integrin or recognizing the mesenchymal marker vimentin, was performed as described in Material and Methods to evaluate the percentages of
cells positive for the EMT markers. Similarly, to TGFb1 stimulation, FGF2 treatment induces a drastic decrease in the percentage of cells showing
the plasma membrane staining for the epithelial markers as well as the appearance in a significant percentage of cells of the cytosolic and fila-
mentous signal of the mesenchymal marker vimentin. In contrast, KGF/FGF7 treatment does not modify the pattern of staining observed in unsti-
mulated (-GFs) cells. The FGF2-induced effects are abolished in the presence of the specific FGFR tyrosine kinase inhibitor SU5402. The
quantitative analysis was performed and the cut-off of the signal intensity was selected as described in Material and Methods. Results are
expressed as mean values 6 SD. Student’s t test was performed as reported in Material and Methods and significance level has been defined as
follows: *, ***, ^^ p<0.001 vs the corresponding untreated cells, **, ^, ^^^ p<0.001 vs the corresponding FGF2-treated cells. Bar: 10 mm [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 5.
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controlled by ESRPs and that E5 expression down-modulates
them inducing switching from FGFR2b to FGFR2c, RT-PCR
was performed as above on W12p6 cells compared with
HaCaT keratinocytes and human dermal fibroblasts (HFs):
concomitant with the decreased transcript levels of FGFR2b
and a nonphysiological expression of FGFR2c (Fig. 5a), also
the ESRP1 and ESRP2 mRNAs were much lower respect to the
HaCaT keratinocytes (Fig. 5b). In addition, the overexpression
of ESRP1, performed by transient transfection with pMXs-
IRES-blast2 Esrp1-FF (W12p6 ESRP1) or with empty vector
(W12p6 EV), was able to induce a significant increase in the
mRNA expression of the FGFR2b variant (Fig. 5c, central
panel) and a decrease in that of FGFR2c (Fig. 5c, right panel)
in W12p6 ESRP1 cells respect to W12p6 EV control cells, pro-
viding a further evidence in favor of the key role played by the
ESRPs in the splicing event also in this cellular model.
Finally, to demonstrate the direct role exerted by 16E5 on
the receptor isoform switching, we analyzed the effects of the
depletion of the viral protein in W12p6 cells using small
interfering RNA for 16E5 (E5 siRNA) or control siRNA as
described in Material and Methods. We first performed
experiments on HaCaT cells by cotransfection of E5-HA
cDNA and E5 siRNA to verify the efficiency of 16E5 silenc-
ing through real-time RT-PCR and western blot analysis
using anti-HA monoclonal antibody, confirming the efficient
depletion of the 16E5 protein in E5 siRNA-transfected cells
(Fig. 5d). The equal loading was assessed with anti-actin anti-
body (Fig. 5d). Then we transfected W12p6 cells with the E5
siRNA or with the control siRNA and we evaluated the E5
gene expression silencing at the transcript level by real-time
RT-PCR (Fig. 5e). In agreement with our working hypothesis
that 16E5 expression induces FGFR2b/2c switch, depletion of
the viral protein led to an increase of the mRNA levels of
either ESRP1 or ESRP2 (Fig. 5f, left panels) and to a restored
expression of FGFR2b associated with a decrease of the
FGFR2c isoform (Fig. 5f, right panels).
Discussion
In light of our previous results proposing the functional
crosstalk among the viral protein HPV16 E5 and the growth
factor receptor FGFR2b/KGFR and their opposite roles
played in epithelial carcinogenesis,12,13 the present study was
focused on the possible dysregulated FGFR2 splicing and
consequent EMT triggering which may occur in early stages
of HPV infection: our results, confirming our starting
hypothesis, suggest that these molecular events would repre-
sent an additional mechanism of cervical transformation and
tumor progression. In addition, we showed that 16E5 is a
powerful tool for perturbing the epithelial homeostasis con-
trolled by growth factor receptors: in fact, using the cellular
models expressing this viral product, our study might con-
tribute to the ongoing definition of the role of FGF/FGFR
tumor-suppressive or oncogenic signaling as well as of that
played by the FGF-network of autocrine and paracrine inter-
actions between the epithelial context and the stromal
microenvironment.
We demonstrated here that the changes in the expression
of the mutually exclusive splice variants FGFR2b and
FGFR2c, occurring in the presence of 16E5, are the conse-
quence of a ESRP-dependent switch, since the restored expres-
sion of ESRP1 is able to contrast the effect of the viral protein.
These findings provide a further evidence in favor of the pro-
posed major role played by the ESRPs in the FGFR2 switch5
and indicate that oncogenic viral products, such as the HPV16
E5, may act on this molecular mechanism to alter the ligand-
dependent receptor signaling and the epithelial-stromal inter-
actions for cell transformation. Consistent with this expecta-
tion, we showed also that the effects exerted by the viral
protein are synergistic with those observed in response to
TGFb, which is known to trigger the isoform splicing of
FGFRs for driving EMT 6,25 and which appears to be involved
in cervical carcinogenesis.28–30 Because we have recently
reported that the expression of 16E5 down-modulates the
TGFb signaling pathway,23 further work will be addressed to
analyze in detail the FGF and TGFb crosstalk in the unex-
plored context of the HPV-associated early carcinogenesis and
its relationship with the inflammatory microenvironment.
In addition to the evident synergistic and interplaying
roles played by 16E5 and TGFb in FGFR2 switch and EMT
induction, our results appear to suggest that also other
Figure 5. FGFR2b to FGFR2c switch and down-regulation of ESRPs induced by 16E5 in the W12p6 cervical model of HPV early carcinogene-
sis. (a,b) The transcript levels of FGFR2b and FGFR2c (a) and ESRP1 and ESRP2 (b) were quantitated by real-time relative RT-PCR in W12p6
and in HaCaT cells and primary human dermal fibroblasts (HFs). A significant decrease of FGFR2b mRNA and a nonphysiological expression
of FGFR2c (a) are found in W12p6, together with a down-regulation of both ESRP1 and ESRP2 transcript levels (b). (c) Overexpression of
ESRP1 in W12p6 cells by transient transfection (W12p6 ESRP1) induces a significant increase of the FGFR2b mRNA and a decrease in that
of FGFR2c compared to W12p6 EV control cells. (d–f) Silencing of 16E5 in HaCaT E5 cells (d) and in W12p6 cells (e, f) using E5 siRNA or
control siRNA: the western blot analysis was performed using anti-HA monoclonal antibody and the equal loading was assessed with anti-
actin antibody (d). The efficient depletion of 16E5 at both transcript and protein levels is evident in HaCaT E5 cells (d) as well as at the
mRNA level in W12p6 cells (e). The transcript levels of FGFR2b and FGFR2c and ESRP1 and ESRP2 (f), quantitated by real-time relative RT-
PCR as above, show that the depletion of the viral protein by E5 siRNA leads to an increase of ESRP1 or ESRP2 mRNA (f) and to a restored
expression of FGFR2b associated with a decrease of the FGFR2c isoform (f) compared with W12p6 control siRNA cells. Results are expressed
as mean values 6 SE. Student’s t test was performed as reported in Material and Methods and significance level has been defined as fol-
lows: (a,b) *, **, ***, p<0.05 vs HaCaT cells; (c) ^ and ^^ p<0,05 vs HaCaT cells; ^^^, ^^^^ p<0,05 vs W12p6 EV cells; (d,e) *
p<0,01 vs the corresponding E5 cDNA/ control siRNA or control siRNA cells; (f) ^ p<0.01, ^^ and ^^^^ p<0,05 and ^^^ p<0,005 vs
W12p6 control siRNA.
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mediators of epithelial homeostasis, able to trigger EMT in
keratinocytes and regulated in the presence of 16E5,31 might
participate to the process induced by the viral protein; there-
fore, because the 16E5 functional activity, leading to pertur-
bation of cell growth and behavior,32 is mainly exerted on
differentiating cells,13,33 future work will be focused in com-
paring the effects of the viral product in undifferentiated ver-
sus differentiating keratinocytes to understand if 16E5 could
differently modulate the EMT at different stages of keratino-
cyte differentiation.
Finally, although EMT might result also from HPV16 E6
and E7 expression,26,27 our results indicate that HPV16 E5,
whose expression is known to precede those of E6 and E7,
would play a major role in the EMT associated with the viral
infection, since FGFR2 inhibition in W12p6 cells specifically
blocks the process. In this scenario of early molecular drivers
of viral oncogenesis, 16E5 would change the cell response to
the microenvironmental growth factors and in turn would
induce EMT through FGFR2 switch and nonphysiological
expression of the FGFR2c isoform.
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